<DOC>
	<DOCNO>NCT00390000</DOCNO>
	<brief_summary>RATIONALE : Vatalanib pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . Vatalanib may also stop growth tumor cell block blood flow tumor . Giving vatalanib together pemetrexed disodium may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vatalanib give together pemetrexed disodium treat patient advance solid tumor .</brief_summary>
	<brief_title>Vatalanib Pemetrexed Disodium Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . To determine dose limit toxicity ( DLT ) maximally tolerate dose ( MTD ) PTK/ZK pemetrexed disodium give combination . II . To describe toxicity associate combination PTK/ZK pemetrexed disodium . III . To evaluate pharmacokinetic interaction combination PTK/ZK pemetrexed disodium MTD ( Group II ) . IV . To evaluate intracellular content pemetrexed disodium polyglutamates measure activity pemetrexed disodium transport activation enzymes MTD expansion cohort ( Group II ) . V. To evaluate polymorphism gene expression pemetrexed disodium target gene , gene encode enzyme involve transport , activation , inactivation pemetrexed disodium , correlate haplotype-tagged SNPs gene expression level intracellular level pemetrexed disodium polyglutamates , toxicity and/or efficacy pemetrexed disodium Group II . VI . To evaluate pharmacogenetic , metabolic clinical marker may predict hypertension induce anti-VEGF therapy . OUTLINE : This dose-escalation study vatalanib . Patients assign 1 2 treatment group . GROUP I ( dose escalation , close accrual 12/18/2007 ) : Patients receive pemetrexed disodium IV 10 minute day 1 oral vatalanib twice daily day 1-21 . GROUP II ( MTD expansion group ) : Patients receive pemetrexed disodium IV day 1 , group I . Patients also receive oral vatalanib MTD twice daily day 8-21 course 1 day 1-21 subsequent course . In group , course repeat every 21 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Willingness return Mayo Clinic Rochester follow Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry , duration study participation , least 30 day last administration study medication ECOG performance status ( PS ) 0 , 1 , 2 Histologic proof advance solid tumor know standard therapy potentially curative definitely capable extend life expectancy upon registration . Mandatory translational research ( MTD patient ) : willingness provide biologic specimen require protocol ; willingness undergo brachial artery ultrasound measurement ANC &gt; = 1500/uL Hgb &gt; = 9 g/dL PLT &gt; = 100,000/uL AST = &lt; 3 x ULN AST = &lt; 5 x ULN liver involvement Calculated creatinine clearance &gt; = 45 ml/min Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Random urine protein : osmolality ratio = &lt; 0.40 OR total urinary protein = &lt; 500 mg measure creatinine clearance ( CrCl ) &gt; = 45 mL/min 24hour urine collection Patients contraindication intake folic acid , vitamin B12 dexamethasone For patient pleural/peritoneal/pericardial effusion : If patient asymptomatic effusion volume approximate &gt; 500 mL produce measurable objective change relate effusion ( e.g. , echocardiographic ventricular compression , hypoxia pulse oximetry , etc . ) , effusion drain Able permanently discontinue aspirin dose &gt; =1.3 grams/day &gt; =10 day &gt; = 10 day pemetrexed disodium treatment Life expectancy &gt; = 12 week Symptomatic , untreated , uncontrolled CNS metastases seizure disorder ; patient CNS metastasis treat whole brain radiation ( WBRT ) may enrol completion WBRT ; patient may begin chemotherapy early next day WBRT Any clinically significant infection Active , bleed diathesis anticoagulant HIVpositive patient receive combination antiretroviral therapy possible pharmacokinetic interaction PTK/ZK Chemotherapy = &lt; 3 week prior registration Radiation &gt; = 30 % bone marrow Immunotherapy = &lt; 2 week prior registration Chronic renal disease Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) Impairment gastrointestinal ( GI ) function GI disease since may significantly alter absorption PTK/ZK ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Greater ( &gt; ) normal risk bleed anticoagulant Pregnant , nursing , positive pregnancy test = &lt; 7 day prior registration woman childbearing potential Symptomatic serosal effusion ( &gt; = CTCAE v3.0 grade 2 dyspnea amenable drainage prior registration ) Mitomycin C/nitrosoureas , bevacizumab = &lt; 6 week prior registration Biologic therapy = &lt; 2 week prior registration Other chemotherapy , immunotherapy , hormonal therapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDA approve indication context research investigation ) = &lt; 4 week prior registration Prolonged QTc ( &gt; 450 msec male &gt; 470 msec female ) know history congenital acquire prolonged QTc syndrome Serious condition , opinion investigator , would compromise patient 's ability complete study Prior therapy monoclonal antibody VEGF , VEGF trap , small molecule receptor tyrosine kinase activity VEGFR , antisense oligonucleotide therapy VEGF mRNA allow Full field radiation therapy = &lt; 4 week prior registration limit field radiation therapy = &lt; 2 week prior registration ( site previous radiotherapy evidence progressive disease site disease ) Men woman childbearing potential unwilling employ adequate contraception ( barrier method birth control ) ( oral , implantable , injectable contraceptive may affect cytochrome p450 interaction , therefore , consider effective study ) ) Labile hypertension , history poor compliance antihypertensive medication ) Myocardial infarction = &lt; 6 month prior registration h ) History deep venous thrombosis pulmonary embolism = &lt; 2 year prior registration Current use follow drug : amiodarone ; anticoagulant ( e.g. , warfarin ) ; antiretroviral therapy ( e.g. , ritonavir ) ; carbamazepine ; chlorpromazine ; cisapride ; clarithromycin ; clopidogrel ; disopyramide ; droperidol ; erythromycin ; fondaparinux ; haloperidol ; heparin ; itraconazole ; ketoconazole Current use follow drug : methadone ; oral contraceptive ; phenobarbital ; phenytoin ; procainamide ; product contain grapefruit juice ; quinidine ; rifabutin ; rifampin ; sotalol ; sparfloxacin ; St. John 's Wort ; thioridazine ) Patients require chronic treatment PPI ( e.g. , omeprazole , lansoprazole , etc . ) H2 antagonist ( e.g. , ranitidine , famotidine , etc . ) Major surgery ( i.e. , laparotomy ) , open biopsy , significant traumatic injury = &lt; 4 week prior registration ; minor surgery = &lt; 2 week prior registration ; insertion vascular access device consider major minor surgery regard b ) Angina pectoris c ) History congestive heart failure = &lt; 3 month prior registration , unless ejection fraction &gt; 45 % f ) Diabetes g ) Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Patients receive prior treatment use pemetrexed disodiumcontaining regimen = &lt; 12 month prior registration Any follow concurrent severe and/or uncontrolled medical condition : e ) Cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>